Evidence map›Paper›PMID 29805438›Full record

ArticleInternational journal of biomedical imaging2018

Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases.

Mohammed Q Qutaish, Zhuxian Zhou, David Prabhu, Yiqiao Liu, Mallory R Busso, Donna Izadnegahdar, Madhusudhana Gargesha, Hong Lu, Zheng-Rong Lu, David L Wilson

Abstract read
In one paragraph

Article in International journal of biomedical imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A hyperspectral approach for recovering agent excretion biodistributions using whole-body fluorescence cryo-imaging.Proceedings of SPIE--the International Society for Optical Engineering · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammed Q QutaishDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Zhuxian ZhouDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
David PrabhuDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Yiqiao LiuDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Mallory R BussoDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Donna IzadnegahdarDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Madhusudhana GargeshaBioInVision Inc., Suite E, 781 Beta Drive, Cleveland, OH 44143, USA.
Hong LuDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Zheng-Rong LuDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
David L WilsonDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.ORCID 0000-0001-9763-1463

Funding

Biodegradable Macromolecular Blood Pool Contrast AgentsR01EB000489 · NIBIB · UNIVERSITY OF UTAH · PI LU, ZHENG-RONG · 2003 to 2014
$3.3M
Image-guided EMT inhibition for treating metastatic breast cancerR01CA194518 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LU, ZHENG-RONG, SCHIEMANN, WILLIAM · 2015 to 2019
$2.4M
Cancer Imaging and Therapy Analysis Platform (CITAP)R44CA213601 · NCI · BIOINVISION, INC. · PI GARGESHA, MADHUSUDHANA, WILSON, DAVID LYNN · 2018 to 2019
$1.6M
Cancer Imaging and Therapy PlatformR41CA213601 · NCI · BIOINVISION, INC. · PI WILSON, DAVID LYNN · 2016 to 2016
$224k
NCI NIH HHS R01 CA194518NCI NIH HHS R41 CA213601NCI NIH HHS R44 CA213601NIBIB NIH HHS R01 EB000489
6 · The paper itself

Abstract

We created and evaluated a preclinical, multimodality imaging, and software platform to assess molecular imaging of small metastases. This included experimental methods (e.g., GFP-labeled tumor and high resolution multispectral cryo-imaging), nonrigid image registration, and interactive visualization of imaging agent targeting. We describe technological details earlier applied to GFP-labeled metastatic tumor targeting by molecular MR (CREKA-Gd) and red fluorescent (CREKA-Cy5) imaging agents. Optimized nonrigid cryo-MRI registration enabled nonambiguous association of MR signals to GFP tumors. Interactive visualization of out-of-RAM volumetric image data allowed one to zoom to a GFP-labeled micrometastasis, determine its anatomical location from color cryo-images, and establish the presence/absence of targeted CREKA-Gd and CREKA-Cy5. In a mouse with >160 GFP-labeled tumors, we determined that in the MR images every tumor in the lung >0.3 mm

Identifiers

PMID29805438
PMCPMC5899875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.